Carvolix CVX

Claret Capital Partners provides €30m financing to Carvolix to accelerate commercialization of medtech portfolio Carvolix is a listed French commercial- and clinical-stage medical technology companyDeveloping breakthrough AI-driven mini-robots and biomimetic implants to revolutionize interventional cardiology and the treatment of ischaemic stroke Lead technology, TAVIpilot, an FDA-cleared, easy-to-use, AI-driven intraoperative software for TAVI (Transcatheter Aortic Valve Implantation) procedure

PARIS, August 04, 2026--Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mu

PARIS & LYON, France, July 29, 2026--PK MED, a French biotechnology company founded by Truffle Capital (founder of Abivax and Carvolix), developing therapeutic micro-implants to address major medical needs, today announces a significant strengthening of its governance. The company is strengthening the structure of its Board of Directors and Scientific Advisory Board to support the upcoming Phase 2 entry of its most advanced drug candidate, ARTHRELIS (treatment of gout flares), and to accelerate